IP Library Granted Patent US 8,809,351
Granted Patent B2
US 8,809,351 · App. 13/761,056 · Granted Aug 19, 2014

Antiviral compound and cox-2 inhibitor combination therapy for functional somatic syndromes, including combination of famciclovir and celecoxib

Inventor: William L. Pridgen (Tuscaloosa, AL)
Assignee: Innovative Med Concepts, LLC.
A61K31/635A61K31/522A61K45/06A61K31/5415A61K31/415A61K31/52A61K31/196
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,351
App. No.
13/761,056
Granted
Aug 19, 2014
Kind
B2
Abstract

The present invention relates to methods of treating fibromyalgia, by administering a therapeutically-effective combination of an antiviral component and a COX-2 inhibitor component. The invention is further related to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is also related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and celecoxib.

Claims (10)

1. A fixed-dose drug-combination comprising famciclovir and celecoxib in a chronic-disease-treatment-effective coacting-combination-dosage amount, wherein the amount of famciclovir is present in a unit dosage form to provide a total daily dose in a range of about 500 mg to about 2000 mg, and wherein the amount of celecoxib is present in a unit dosage form to provide a total daily dose in a range of about 350 mg to about 400 mg.

2. The fixed-dose drug-combination of claim 1 , wherein the amount of famciclovir is present in a unit dosage form from about 125 mg to about 500 mg, wherein the total daily dose of famciclovir is in a range of about 500 mg to about 2000 mg.

3. The fixed-dose drug-combination of claim 1 , wherein the amount of celecoxib is present in a unit dosage form from about 100 mg to about 200 mg, wherein the total daily dose of celecoxib is in a range of about 350 mg to about 400 mg.

4. The fixed-dose drug-combination of claim 1 , wherein the amount of famciclovir is present in a unit dosage form to provide a total daily dose in a range from about 500 mg to about 1000 mg, and wherein the amount of celecoxib is present in a unit dosage form to provide a total daily dose of about 400 mg.

5. The fixed-dose drug-combination of claim 1 , comprising famciclovir and celecoxib in a fibromyalgia treatment-effective combination-dosage-amount.

6. A drug-combination therapy comprising famciclovir and celecoxib in a chronic-disease-treatment-effective coacting-combination-dosage amount, wherein the amount of famciclovir is present in a total daily dose in a range of about 500 mg to about 2000 mg, and wherein the amount of celecoxib is present in a total daily dose in a range of about 350 mg to about 400 mg.

7. The drug-combination therapy of claim 6 , wherein the amount of famciclovir is present in a unit dosage form from about 125 mg to about 500 mg, wherein the total daily dose of famciclovir is in a range of about 500 mg to about 2000 mg.

8. The drug-combination therapy of claim 7 , wherein the amount of celecoxib is present in a unit dosage form from about 100 mg to about 200 mg, wherein the total daily dose of celecoxib is in a range of about 350 mg to about 400 mg.

9. The drug-combination therapy of claim 8 , wherein the amount of famciclovir is present in a unit dosage form to provide a total daily dose in a range from about 500 mg to about 1000 mg, and wherein the amount of celecoxib is present in a unit dosage form to provide a total daily dose of about 400 mg.

10. The drug-combination therapy of claim 9 , wherein the combination therapy comprises famciclovir and celecoxib in a fibromyalgia treatment-effective combination-dosage-amount.

Assignments (4)
CHANGE OF NAME Recorded Jan 16, 2025
From: VIRIOS THERAPEUTICS, INC.
To: DOGWOOD THERAPEUTICS, INC.
Reel/Frame 069934/0756 →
CHANGE OF NAME Recorded Jul 12, 2023
From: INNOVATIVE MED CONCEPTS, LLC
To: VIRIOS THERAPEUTICS, LLC
Reel/Frame 064265/0418 →
ENTITY CONVERSION Recorded Jul 12, 2023
From: VIRIOS THERAPEUTICS, LLC
To: VIRIOS THERAPEUTICS, INC.
Reel/Frame 064593/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2013
From: PRIDGEN, WILLIAM L., MD
To: INNOVATIVE MED CONCEPTS, LLC,
Reel/Frame 031652/0683 →
Continuity (2)
Provisional Application 61595507 · Feb 6, 2012
Related Publication 20130203710A1 · Aug 8, 2013